Skip to content

The effect of dexmedetomidine nasal spray combined with thoracic paravertebral nerve block on sleep and pain in patients with herpes zoster neuralgia

The effect of dexmedetomidine nasal spray combined with thoracic paravertebral nerve block on sleep and pain in patients with herpes zoster neuralgia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109200
Enrollment
Unknown
Registered
2025-09-15
Start date
2024-09-15
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

the control group (Group C) :According to the standard pharmacological treatment in pain management, the patient is prescribed pregabalin (one capsule morning and evening), oxycodone/acetaminophen (on
the dexmedetomidine group (Group D).:According to the standard pharmacological treatment in the pain department, the patient is prescribed oral pregabalin (one capsule twice daily, morning and evening

Sponsors

Jiangsu Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-80 years, regardless of gender. (2) Clearly diagnosed with thoracic and back herpes zoster neuralgia (HZN), accompanied by obvious allodynia and hyperalgesia. (3) Sleep is affected (VAS score = 4 points).

Exclusion criteria

Exclusion criteria: (1) A history of chronic rhinitis. (2) Preoperative sick sinus syndrome, severe sinus bradycardia (heart rate < 50 beats/min), second-degree or higher atrioventricular block, permanent pacemaker implantation, severe heart failure, or ejection fraction < 30%. (3) A history of cerebral hemorrhage or stroke, and insufficiency of important organ functions such as heart, brain, and kidney (Child-Pugh grade B or C, chronic kidney disease stage 3-5). (4) A history of taking sedatives, antidepressants, or other psychotropic drugs for depression or sleep disorders. (5) Allergies to the study drugs. (6) Severe dementia, low cognitive function, language disability, severe hearing or visual impairment, mental disorders, coma, or any other diseases that would hinder the completion of the study.

Design outcomes

Primary

MeasureTime frame
Total Sleep Time;

Secondary

MeasureTime frame
Deep Sleep Time;Light Sleep Time;Rapid Eye Movement Sleep Time;Number of Awakenings;Visual analogue scale;

Countries

China

Contacts

Public ContactSun Xiaodi

Jiangsu Provincial People's Hospital

sun321victor@163.com+86 139 5209 8007

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026